CXCL8 and nonpapillary renal cell carcinoma: Interleukin (IL)-8 expression is elevated, during sunitinib resistance, which suggests that IL-8 is also an key contributor and a potential therapeutic target to reverse sunitinib resistance in ccRCC [35].